For imputation, the package mice (v 3.13.0) was used
On the one hand, you could be experiencing diarrhea
Last but not least, by reducing the dose and avoiding systemic distribution, nasal delivery of GLP-1 drugs should alleviate gastrointestinal and other adverse events, offering a promising approach for maximizing the therapeutic effects GLP-1 drugs with potentially increased compliance and safety
Obesity can increase the risk of type 2 diabetes, heart disease and certain cancers
This mechanism of action led to the initial approval of GLP-1 RAs to manage type 2 diabetes
For patients with obesity, metabolic disorders, or poor blood sugar control, the drug has been showing promising results in reducing starting weight and improving insulin sensitivity